At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 315 enrolled
Drug / intervention
Candesartan +3 moredrug
Likely dose
Candesartan 16 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Non-comparative, Phase IV Study to Evaluate the Effect of Candesartan Based Therapy in the Percent Change of proBNP Level After 24 Week Treatment in the Patients With Hypertension With Left Ventricular Hypertrophy
In Brief
A Phase 4 clinical trial evaluating Candesartan and Felodipine for Hypertension and Left Ventricular Hypertrophy. Completed, enrolled 315 participants across 11 sites.
Detailed Summary
The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hypertrophy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Left Ventricular Hypertrophy
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJul 2006
Primary CompletionJun 2008
TodayJul 2026
First PostedJul 6, 2006
Enrollment StartJun 1, 2006
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.0 years ago
Interventions
Candesartandrug
16 mg once daily in oral tablet form
Candesartandrug
32 mg once daily in oral tablet form
Felodipinedrug
5 mg once daily in oral tablet form
Felodipinedrug
10 mg once daily in oral tablet form